CFLAR and melanoma: The extrinsic pathway of apoptosis, which activates caspases independent of mitochondria, can also be targeted by HDAC inhibitors which reduce levels of c-FLIP—an inhibitor of TNF-related apoptosis inducing ligand (TRAIL)—the class I HDAC inhibitor MS-275 rendered melanoma more sensitive to TRAIL killing [92,99].